Tag

Rescheduling

All articles tagged with #rescheduling

politics26 days ago•12 min saved

Barr and Sabet Warn Against Marijuana Rescheduling Over Health Risks

Former Trump-era Attorney General William Barr and anti-legalization advocate Kevin Sabet publish a Washington Post op-ed arguing marijuana has horrific health risks, offers no proven medical value, and should not be rescheduled; the piece comes as the DEA weighs broader rescheduling amid testimony on medical benefits, even as a 2023 HHS analysis acknowledged some medical value. Opponents warn that rescheduling could unlock tax deductions under 280E and boost industry marketing, while lawsuits continue challenging the process.

via marijuanamoment.net|

#barrsabet #dea #marijuana

policy1 month ago•7 min saved

Opponents Seek Stay on Cannabis Rescheduling Over Costs and Abuse Concerns

A drug-testing industry group (NDASA) and MMJ International Holdings urge a DC court to pause the government’s move to reschedule cannabis from Schedule I to Schedule III, arguing the change would raise drug-testing costs, create liability risks, and potentially increase marijuana abuse; they contend the challengers have standing and that the rulemaking was improper, as three consolidated lawsuits proceed and a DEA hearing continues, while opponents warn the policy would harm public safety and the industry’s ability to operate.

via Marijuana Moment|

#cannabis #drug-testing #federal-policy

policy1 month ago•7 min saved

DEA and FDA Push to Reschedule Marijuana, Emphasizing Medical Use and Lower Harms

Opening day of a cannabis rescheduling hearing features DEA and FDA arguing that marijuana has medical benefits and lower day-to-day harms than alcohol or opioids, supporting moving it from Schedule I to Schedule III. Testimony describes real-world pain management benefits and relatively mild withdrawal, while opponents criticize the analysis and allege shifting precedent. The process continues through July 15 amid lawsuits and broader regulatory implications, including tax guidance, workplace rules, and updates to related federal forms and enforcement.

via Marijuana Moment|

#dea #drug-policy #fda

politics2 months ago•9 min saved

DEA Blocks Agency Witness Ahead of Marijuana Rescheduling Hearing

The DEA told SAM it will not identify Luli Akinfiresoye, a DEA pharmacologist, as a witness for SAM’s case in the upcoming hearing on moving marijuana from Schedule I to Schedule III, citing Touhy regulations and potential Privacy Act protections. SAM had sought to question the official about cannabis harms, but the DEA says any testimony would require a formal Touhy request and could be shielded. The hearing, overseen by Administrative Law Judge Derek Julis, runs June 29 to July 15 and has drawn complaints over access, including a push to livestream, which the judge previously barred; multiple lawsuits challenge the process as the government defends the scheduling move that could unlock federal benefits for state-legal cannabis businesses.

via Marijuana Moment|

#dea #hearing #marijuana

policy2 months ago•5 min saved

DEA Launches On-Site Inspections of Dispensaries Registering Under Cannabis Rescheduling Plan

The DEA has begun on-site inspections of medical marijuana dispensaries that filed registration to receive federal protections under the Trump-era cannabis rescheduling move. In Mississippi, two operators were visited by 5–6 agents for about six hours each, with investigations focusing on a broad range of records and processes, from ownership and licensing to inventory, security, and patient intake procedures. The registrations aim to move medical cannabis from Schedule I to Schedule III, enabling tax deductions under 280E, and the DEA plans to roll out new forms for other state-licensed medical marijuana businesses. Tax guidance from the IRS and related regulatory updates (ATF gun form changes, CRS analysis) are also anticipated, as hearings on broader rescheduling approach proceed.

via Marijuana Moment|

#dea #dispensaries #marijuana

politics2 months ago•12 min saved

AGs Challenge Federal Marijuana Rescheduling

Three Republican state attorneys general from Indiana, Nebraska and Louisiana filed a lawsuit in the D.C. Circuit challenging the DOJ’s move to reschedule cannabis from Schedule I to Schedule III, arguing improper rulemaking and overreach of authority. The suits were consolidated with a SAM/NDASA case, naming the DOJ, the DEA, and Acting Attorney General Todd Blanche as defendants. A broader administrative hearing on rescheduling is expected, while SAM warns the order could harm public health and safety.

via Marijuana Moment|

#cannabis #doj #lawsuit

policy3 months ago•6 min saved

DOJ's partial rescheduling of cannabis leaves federal legalization unresolved

The DOJ moved certain marijuana products—from FDA-approved items to state-licensed medical cannabis—from Schedule I to Schedule III, a narrow step that allows medical prescriptions but does not legalize cannabis federally or for recreation. Enforcement remains discretionary, and ongoing lawsuits challenge the order, while states continue operating under a patchwork system with broad public support for legalization but no federal change on the horizon.

via USA Today|

#department-of-justice #federal-state-conflict #legalization

policy3 months ago•7 min saved

Congressional CRS: Medical Cannabis Rescheduling Is a Limited Federal Opening

CRS says moving medical cannabis from Schedule I to III signals medical value and could allow some state-licensed medical cannabis businesses and researchers to operate with fewer federal barriers and may enable 280E tax deductions, but it does not fully legalize recreational marijuana or bring the entire state-legal industry into CSA compliance; many penalties remain under the CSA, and full compliance will depend on further federal action and upcoming hearings, with ongoing research and regulatory considerations plus an expedited DEA registration process for compliant medical-license holders.

via Marijuana Moment|

#crs #federal-law #marijuana

politics3 months ago•4 min saved

Partial cannabis rescheduling fuels federal policy confusion

The Trump administration moved state-licensed medical cannabis products and FDA-approved cannabis products from Schedule I to Schedule III, a partial rescheduling that doesn’t fully normalize cannabis at the federal level. Experts say this is not a broad reclassification and hinges on future FDA decisions, leaving implementation unclear and raising questions about protections for patients, housing and employment, and equity for minority entrepreneurs. A June 29 DEA hearing on rescheduling adds to the uncertainty amid ongoing debate about alignment with the UN Single Convention and overall public support for full legalization.

via The Guardian|

#cannabis #dea #drug-policy

politics4 months ago•12 min saved

Tax Guidance Ahead as Marijuana Is Reclassified to Schedule III

Federal officials say they will issue new tax guidance for the marijuana industry after the Trump administration reclassified cannabis so state-licensed medical cannabis moves to Schedule III while recreational cannabis remains Schedule I for now; the change is not a federal legalization but could allow medical cannabis businesses to deductions and credits previously blocked by IRS 280E. The guidance is expected to explain how expenses should be allocated for entities with both medical and recreational activities, with possible retrospective relief in some years, and comes as a summer hearing process considers broader rescheduling. Separately, the DOJ said rescheduling doesn’t change gun-rights considerations in a pending case, and Trump praised the medical benefits of cannabis.

via Marijuana Moment|

#280e #marijuana #politics

politics4 months ago•6 min saved

Trump reclassifies marijuana to Schedule III to boost medical research

The Trump administration moved to shift marijuana from Schedule I to Schedule III to expand medical research access, limited to FDA-approved products or state-legal medical cannabis, with an administrative hearing set for June 29 to speed broader rescheduling. The move, rooted in a December executive order, does not legalize cannabis federally but includes tax relief for cannabis companies and could lend legitimacy to regulated medical programs. Reactions are mixed: supporters praise the shift as overdue progress, while some Republicans and critics worry it may advance industry interests over public health.

via Politico|

#doj #fda #marijuana

politics4 months ago•3 min saved

Cannabis moved to Schedule III, easing research and banking while federal legalization remains off the table

The Trump administration moved cannabis from Schedule I to Schedule III under the DEA, easing federal research barriers and allowing FDA-approved products and state-licensed items to be treated as Schedule III, while opening banking access and tax deductions for cannabis businesses. An expedited June hearing will also consider formal reclassification back to Schedule I at the federal level, signaling a broader, cautious shift in federal cannabis policy without legalizing it federally.

via CNBC|

#banking #cannabis #politics

politics6 months ago•14 min saved

GOP Lawmaker Pushes 20-Year Timeline to Reschedule Marijuana

Rep. Andy Harris (R-MD) says the Justice Department should take about 20 years to reschedule marijuana from Schedule I to Schedule III, arguing that the process moves slowly and that internal DOJ disagreements may be delaying action, even as Trump’s order to accelerate the rule remains pending; other lawmakers indicate readiness to act when opportunities arise, while DOJ has offered little public comment amid shifting political dynamics such as redistricting.

via Marijuana Moment|

#cannabis-policy #congress #doj

policy8 months ago•6 min saved

Legal Challenge to RV Regulations

President Trump's executive order aims to reschedule marijuana to Schedule III, potentially easing restrictions and boosting medical research, but the process is complex and may not lead to immediate legal or financial changes for cannabis businesses, with ongoing legal and regulatory hurdles.

via LAist|

#cannabis-research #federal-law #marijuana

health-and-policy8 months ago•5 min saved

Potential Impact of Marijuana Reclassification on Research and Policy

President Trump signed an executive order to prompt the Department of Justice to reclassify marijuana from Schedule I to Schedule III, which could ease banking and tax issues for cannabis businesses and potentially influence future medical and recreational use policies, but it does not legalize marijuana federally or allow crossing state lines with it.

via Colorado Public Radio|

#cannabis-industry #federal-law #health-and-policy